Aeterna Zentaris returns to profit
Aeterna Zentaris Inc said on Wednesday that it returned to a fourth-quarter profit, as the Canadian drugmaker benefited from higher licensing fees and lower research expenses.
Quebec City late-stage cancer drug developer Aeterna Zentaris Inc. Tuesday posted a third-quarter net loss of $10.1 million, down from a loss of $11.3 million a year earlier, on revenue of $5.7 million, down from $8.6 million.